Floatz logo

Palifermin

Hodgkin's Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB

View all 50 →

Same molecule, other indications

Palifermin is also rated in:

mucositisDormant
BB
Indicative ·
64 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →